Immuneering Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Immuneering Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | $317.0K | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.08M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $2.31M | Mar 10, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 1, 2024 |
| FY2023 | Dec 31, 2022 | $158.8K | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $926.9K | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $1.03M | Mar 10, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.02M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($61.04M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($53.47M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($50.51M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($33.54M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($17.04M) | Mar 10, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.38M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($64.07M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($58.41M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($51.74M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($33.89M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($17.08M) | Mar 10, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.05M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $47.96M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $41.62M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $36.27M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $26.54M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $15.00M | Mar 10, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.34M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($55.00M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($48.97M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($44.10M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($30.85M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($14.62M) | Mar 10, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.2K | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $84.9K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $342.7K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $742.5K | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $60.8K | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $53.4K | Mar 10, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $231.99M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $52.71M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $102.58M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $122.37M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $166.70M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $38.42M | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.50M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $11.33M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $12.01M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $12.52M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.72M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $2.80M | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $218.48M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $41.39M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $90.58M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $109.85M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $155.98M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($22.48M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($6.53M) | Mar 10, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.69M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $6.69M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $6.69M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $6.69M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.70M | Mar 6, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($280.32M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($224.30M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($163.26M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($109.79M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($59.27M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($25.74M) | Mar 10, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.65M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $36.14M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $59.41M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $72.64M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $74.89M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $37.09M | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 10, 2022 |